We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App




POC Analyzer Compared with HPLC Method

By LabMedica International staff writers
Posted on 20 Jun 2017
The measurement of the glycated fraction of hemoglobin (HbA1c) has been recommended to diagnose diabetes, in addition to monitoring glycemic control. More...
HbA1c reflects long-term glycemic control over the preceding two to three months as opposed to glycemic control at a single point in time.

Point of Care Testing (POCT) enables measurement of HbA1c in a clinical setting without the waiting time associated with laboratory testing or the high level of expertise required; however, for POCT methods to be used effectively they must be comparable to those used in a clinical laboratory.

Scientists at Swansea University assayed EDTA blood samples from 100 subjects with and without diabetes. HbA1c was determined using the BioRad D10 high performance liquid chromatography (HPLC) analyzer as the laboratory reference method and the Quo-Test POCT analyzer. The BioRad D10 required 10 μL and the Quo-Test 4 μL of whole blood. Quality control was carried out every day of testing using BioRad Lyphocheck Hemoglobin A1C Controls for the D10 and EKF Diagnostics Quo-Test A1c Controls for the Quo-Test.

The investigators found a median HbA1c was 60 mmol/mol (Interquartile range (IQR) 44.0–71.2) (7.6% (6.17–8.66)) and 62 mmol/mol (45.0–69.0) (7.8% (6.27–8.46) for D10 and Quo-Test, respectively, with very good agreement. Mean (range) intra- and inter-assay variation was 1.2% (0.0–2.7%) and 1.6% (0.0–2.7%) for the D10 and 3.5% (0.0–6.7%) and 2.7% (0.7–5.1%) for the Quo-Test. Mean change in HbA1c after 28 days storage at −20 °C was −0.7% and +0.3% for D10 and Quo-Test respectively. Compared to the D10, Quo-Test showed 98% agreement for the diagnosis of glucose intolerance, impaired glucose tolerance and type 2 diabetes mellitus (T2DM) and 100% for the diagnosis of T2DM.

The authors concluded that the performance of the Quo-Test POCT analyzer is similar to that of a laboratory HPLC analyzer and good agreement was found between the D10 and Quo-Test and seen across a wide HbA1c range. The Quo-Test POCT analyzer should be considered for diagnostic purposes by the various professional organization that issue clinical guidelines. The study will be published in the August 2017 issue of the journal Practical Laboratory Medicine.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.